The US Surgical Matrices Market saw growth in Q317 as sales of allografts fueled double-digit growth in breast matrices and biosynthetics offset declines in biologics in hernia repair.
By Doug Devens, Senior Analyst Biosurgery
The US Surgical Matrices market, consisting of hernia repair and breast reconstruction products, continued uneven growth in Q317. Allergan continued to capture share in the overall market, using its growth in allografts to increase its share.
The Q317 US Hernia Repair Matrices market (consisting of synthetics, biologics and biosynthetic), again had minimal gains, as significant declines continued in biologics (allografts and xenografts) while synthetics held steady according to BioMedGPS’ SmartTRAK Financial Dashboard. While synthetics continue to hold the largest share at...
*This article can only be viewed by SmartTRAK subscribers to this module.